

L&I Pharmacy Spend and Utilization

Prescription Drug Price and Purchasing Summit – Part 1

Jaymie Mai, PharmD

June 14, 2016

Total Drug Spend in CY 2015

- L&I administers the 5th largest workers' compensation program through the State Fund:
 - 2.7 million workers
 - 174,000 employers across the state
- L&I participates in the NW Prescription Drug Purchasing Consortium for rebates and mail-order and the Prescription Drug Program for the PDL
- L&I spent roughly \$17.5 million on prescription drugs in 2015, which is 3.4% of total medical spend



Top 10 Drugs by Cost in CY 2015

RANK	DRUG	THERAPY CLASS	TOTAL SPEND	2015 PUPY SPEND	COST/Rx	PUPY SPEND CHANGE FROM 2014	TOTAL COST CHANGE FROM 2014
1	GABAPENTIN	ANTICONVULSANTS	\$1,208,347.46	\$ 26.39	\$85.42	-\$1.98	-13.0%
2	DULOXETINE HCL	ANTIDEPRESSANTS	\$867,861.07	\$ 18.96	\$240.21	-\$5.40	-27.2%
3	ARIPIPIRAZOLE	ANTIPSYCHOTICS	\$866,233.81	\$ 18.92	\$831.32	-\$20.35	-55.0%
4	ABILIFY	ANTIPSYCHOTICS	\$773,062.59	\$ 16.88	\$1,073.70	-\$22.39	-59.8%
5	LYRICA	ANTICONVULSANTS	\$541,517.99	\$ 11.83	\$476.69	\$2.03	12.9%
6	VENLAFAXINE HCL ER	ANTIDEPRESSANTS	\$380,195.96	\$ 8.30	\$118.22	-\$0.46	-11.4%
7	HARVONI	ANTIVIRALS (HEP C)	\$362,943.00	\$ 7.93	\$24,196.20	\$5.84	255.6%
8	QUETIAPINE FUMARATE	ANTIPSYCHOTICS	\$358,963.51	\$ 7.84	\$231.14	\$0.38	-1.7%
9	BACLOFEN	SKELETAL MUSCLE RELAXANTS	\$347,444.08	\$ 7.59	\$131.26	\$2.85	49.8%
10	CYCLOBENZAPRINE HCL	SKELETAL MUSCLE RELAXANTS	\$311,440.37	\$ 6.80	\$23.50	-\$0.27	-10.1%



OCCUPATIONAL HEALTH **BEST PRACTICES**

WORKING TOGETHER TO KEEP PEOPLE WORKING

Slide 3

Top 10 Drugs by Utilization in CY 2015

RANK	DRUG	THERAPEUTIC CLASS	TOTAL RXs	DAYS SUPPLY	QUANTITY
1	HYDROCODONE-ACETAMINOPHEN	OPIOIDS	15,519	86,458	457,150
2	GABAPENTIN	ANTICONVULSANTS	14,146	400,909	1,579,053
3	IBUPROFEN	NSAIDS	13,910	241,239	757,114
4	CYCLOBENZAPRINE HCL	SKELETAL MUSCLE RELAXANTS	13,251	239,598	508,712
5	NAPROXEN	NSAIDS	10,027	225,076	453,715
6	METHOCARBAMOL	SKELETAL MUSCLE RELAXANTS	8,556	133,080	499,596
7	OXYCODONE-ACETAMINOPHEN	OPIOIDS	7,082	42,251	283,923
8	OXYCODONE HCL	OPIOIDS	6,281	42,459	385,459
9	MELOXICAM	NSAIDS	5,276	147,435	173,352
10	DICLOFENAC SODIUM	NSAIDS	4,152	101,386	204,288



OCCUPATIONAL HEALTH **BEST PRACTICES**

WORKING TOGETHER TO KEEP PEOPLE WORKING

Management Strategies

- Drug Purchasing Consortium and PDL
- Treatment guidelines
- Prior authorization and clinical criteria for coverage or coverage policy
- Fee schedule

Barriers and Challenges

- On-going price increases by manufacturers
- High cost innovative drugs
- Prescribing variation, including off-label uses
- Limited budget



OCCUPATIONAL HEALTH **BEST PRACTICES**

WORKING TOGETHER TO KEEP PEOPLE WORKING